Neurodevelopmental disorders and the role of PSD-95: Understanding pathways and pharmacological interventions
Advanced Neurology · 04.03.2024 · 3 (1) · 2095
DOI: 10.36922/an.2095 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Neurology, online erschienen am 04.03.2024. Verfasst von Gerardo Medina und 1 weiteren Autor:innen. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Neurodevelopmental disorders (NDDs) are often linked to disruption in brain development and present challenges for affected individuals in achieving their cognitive, emotional, and motor developmental milestones. NDDs encompass a spectrum of conditions, including autism spectrum disorder (ASD), schizophrenia (SCZ), attention-deficit hyperactivity disorder (ADHD), and epilepsy. The unequivocal diagnosis of an NDD is often challenging due to overlapping signs and symptoms across different conditions. Synaptic plasticity, the activity-driven modification of synaptic strength and efficacy, plays a crucial role in brain network formation and organization and is frequently altered in NDDs. Here, we explore the multifaceted roles of postsynaptic density-95 kDa (PSD-95) in NDDs. Psd-95 is a scaffolding protein belonging to the membrane-associated guanylate kinases (MAGUKs) family, located at the core of synapses, and is central to synaptic plasticity. Dysregulation of PSD-95 is linked to various neuropsychiatric disorders. In SCZ, decreased PSD-95 expression affects synaptic plasticity, thereby impacting learning and memory. Genes associated with ASD interact with PSD-95, and its removal in mice leads to ASD-like behavioral abnormalities. Furthermore, PSD-95 is implicated in ADHD, where its modulation influences neurotransmission. Medications used in NDD treatment, such as antipsychotic drugs and selective serotonin reuptake inhibitors (SSRIs), can alter PSD-95 levels, potentially influencing synapse formation. Alpha-2 adrenergic agonists might enhance synaptic integrity by impacting PSD-95. Alternative pharmacotherapies such as memantine, allopurinol, and ketamine, all influencing PSD-95 to a certain extent, hold promise in managing NDDs. Understanding the role of PSD-95 in these disorders can deepen our biological comprehension and pave the way for targeted therapies. Specifically, exploring how PSD-95 affects synaptic plasticity and dendritic spine development could uncover opportunities for repurposing drugs to treat NDDs associated with mutations in the DLG4 gene encoding PSD-95.
Zitieren
APA
Medina, G., & MacKenzie, A. E. (2024). Neurodevelopmental disorders and the role of PSD-95: Understanding pathways and pharmacological interventions. Advanced Neurology, 3(1), 2095. https://doi.org/10.36922/an.2095
Vancouver
Medina G, MacKenzie AE. Neurodevelopmental disorders and the role of PSD-95: Understanding pathways and pharmacological interventions. Advanced Neurology. 2024;3(1):2095. doi:10.36922/an.2095
BibTeX
@article{Medina2024,
author = {Medina, Gerardo and MacKenzie, Alex E.},
title = {Neurodevelopmental disorders and the role of PSD-95: Understanding pathways and pharmacological interventions},
journal = {Advanced Neurology},
year = {2024},
volume = {3},
number = {1},
pages = {2095},
doi = {10.36922/an.2095}
}
EUVIMED